UBS AM
INDV icon

UBS AM’s Indivior Pharmaceuticals INDV Stock Holding History

UBS AM’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.99M Buy
194,687
+193,237
+13,327% +$7.01M ﹤0.01% 1375
2026
Q1 		$44.2K Sell
1,450
-196,125
-99% -$6.48M ﹤0.01% 2983
2025
Q4 		$7.09M Sell
197,575
-31,248
-14% -$954K ﹤0.01% 1288
2025
Q3 		$5.52M Buy
228,823
+123,260
+117% +$2.58M ﹤0.01% 1326
2025
Q2 		$1.56M Sell
105,563
-33,310
-24% -$388K ﹤0.01% 2251
2025
Q1 		$1.32M Buy
138,873
+25,173
+22% +$265K ﹤0.01% 2189
2024
Q4 		$1.41M Hold
113,700
– – ﹤0.01% 2211
2024
Q3 		$1.11M Sell
113,700
-43,394
-28% -$508K ﹤0.01% 2348
2024
Q2 		$2.53M Buy
+157,094
New +$2.84M ﹤0.01% 1872

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS AM's INDV Position: Q2 2026 in Review

UBS AM increased its Indivior Pharmaceuticals (INDV) stake by 13,327% in Q2 2026, buying an estimated $7.01M and bringing the position to 194,687 shares worth $7.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1375.

UBS AM first reported a position in INDV in Q2 2024 and has held it in 9 quarters since. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • UBS AM held 194,687 shares of Indivior Pharmaceuticals worth $7.99M as of Q2 2026.
  • UBS AM bought 193,237 Indivior Pharmaceuticals shares in Q2 2026, an estimated $7.01M.
  • Indivior Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1375 holding.
  • UBS AM first reported a position in Indivior Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.